Merck & Co. Stock Surges on Analyst Upgrades and Cancer Vaccine Momentum

Merck & Co.'s stock price has surged to around $150 in early September 2026, driven by analyst upgrades and positive trial results for its personalized cancer vaccine program.

The company's shares have gained about 75.3 percent over the last twelve months, according to data compiled by Altindex, which explains why valuation multiples such as the price-to-earnings ratio stand at elevated levels around 120.3 based on current reported earnings.

A key catalyst for the stock is a price target increase from Wells Fargo & Co., which raised its target from $150 to $170 while maintaining an overweight rating, signaling renewed confidence in the company's valuation upside based on its pipeline and earnings outlook as of September 7, 2026.